AP NEWS

Vaginal Cancer: H1 2018 Pipeline Review - Analysis by Stage of Development, Drug Target, Mechanism of Action, Route of Administration and Molecule Type - ResearchAndMarkets.com

June 5, 2018

DUBLIN--(BUSINESS WIRE)--Jun 5, 2018--The “Vaginal Cancer - Pipeline Review, H1 2018” report has been added to ResearchAndMarkets.com’s offering.

Vaginal Cancer - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Vaginal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Vaginal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Vaginal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 6, 1 and 1 respectively.

Companies Mentioned

Bristol-Myers Squibb Co Fujifilm Holdings Corporation ISA Pharmaceuticals BV MedImmune LLC Merck KGaA Ology Bioservices Inc Ono Pharmaceutical Co Ltd Transgene SA

Key Topics Covered

Introduction Report Coverage Vaginal Cancer - Overview Vaginal Cancer - Therapeutics Development Pipeline Overview Pipeline by Companies Products under Development by Companies Vaginal Cancer - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Vaginal Cancer - Companies Involved in Therapeutics Development Bristol-Myers Squibb Co Fujifilm Holdings Corporation ISA Pharmaceuticals BV MedImmune LLC Merck KGaA Ology Bioservices Inc Ono Pharmaceutical Co Ltd Transgene SA Vaginal Cancer - Drug Profiles durvalumab + tremelimumab - Drug Profile Product Description Mechanism Of Action R&D Progress FF-21101 - Drug Profile Product Description Mechanism Of Action R&D Progress ipilimumab + nivolumab - Drug Profile Product Description Mechanism Of Action R&D Progress ISA-101 - Drug Profile Product Description Mechanism Of Action R&D Progress M-7824 - Drug Profile Product Description Mechanism Of Action R&D Progress nivolumab - Drug Profile Mechanism Of Action R&D Progress NTO-1151 - Drug Profile Product Description Mechanism Of Action R&D Progress TG-4001 - Drug Profile Product Description Mechanism Of Action R&D Progress Vaginal Cancer - Dormant Projects Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation

For more information about this report visit https://www.researchandmarkets.com/research/br85mp/vaginal_cancer?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180605006551/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Women’s Health,Cervical Cancer Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 06/05/2018 02:30 PM/DISC: 06/05/2018 02:30 PM

http://www.businesswire.com/news/home/20180605006551/en

AP RADIO
Update hourly